Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 3/20 | 0.32 |
| ▸ | CA1 | P00915 | 3/20 | 0.32 |
| ▸ | CA9 | Q16790 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5419793 | 1.00 | DNM1 (0.33) | DNM1TSHRLMNACA12CA1 | |
| SCHEMBL7209887 | 0.82 | — | — | |
| SCHEMBL5412874 | 0.81 | — | — | |
| SCHEMBL5412878 | 0.81 | — | — | |
| SCHEMBL3952513 | 0.81 | DNM1 (0.40) | DNM1TSHRCA12CA1CA9 | |
| SCHEMBL5419798 | 0.77 | DNM1 (0.33) | DNM1TSHRLMNACA12CA1 | |
| SCHEMBL22472335 | 0.75 | TSHR (0.38) | DNM1TSHRLMNACA12CA1 | |
| SCHEMBL18165074 | 0.74 | — | — | |
| SCHEMBL182250 | 0.73 | TSHR (0.35) | DNM1TSHRLMNACA12CA1 | |
| SCHEMBL9485027 | 0.72 | CA12 (0.34) | DNM1TSHRLMNACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1504014-B1 | PROCESS FOR PREPARATION OF CYCLIC PRODRUGS OF PMEA AND PMPA | METABASIS THERAPEUTICS INC (US) | 2015-12-02 | — | — | EP | claimed |
| EP-2331558-A2 | PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS | Agilent Technologies, Inc. (US) | 2011-06-15 | — | — | EP | claimed |
| WO-2010034024-A2 | PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. (US) | 2010-03-25 | — | — | WO | claimed |
| US-20070203339-A1 | Process for Preparation of Cyclic Prodrugs of PMEA and PMPA | METABASIS THERAPEUTICS, INC. | 2007-08-30 | — | — | US | claimed |
| US-7193081-B2 | 9-(2-(2,4-cis(S)-4-(3-chlorophenyl)-2-oxo-1,3,2-dioxaphosphor-inan-2 -yl)methoxyethyl)adenine by coupling the dichloridate of 9-(2-phosphonyl- methoxyethyl- or propyl)adenine (PMEA)(PMPA) with a 1-(chlorophenyl) propylene-1,3-diol | METABASIS THERAPEUTICS, INC. (US) | 2007-03-20 | — | — | US | claimed |
| EP-1504014-A4 | PROCESS FOR PREPARATION OF CYCLIC PRODRUGS OF PMEA AND PMPA | METABASIS THERAPEUTICS INC (US) | 2006-06-07 | — | — | EP | claimed |
| EP-1504014-A2 | PROCESS FOR PREPARATION OF CYCLIC PRODRUGS OF PMEA AND PMPA | Metabasis Therapeutics, Inc. (US) | 2005-02-09 | — | — | EP | claimed |
| US-20030225277-A1 | Process for preparation of cyclic prodrugs of PMEA and PMPA | METABASIS THERAPEUTICS, INC. | 2003-12-04 | — | — | US | claimed |
| WO-2003095665-A2 | PMEA AND PMPA CYCLIC PRODUCING SYNTHESIS | METABASIS THERAPEUTICS, INC. (US) | 2003-11-20 | — | — | WO | claimed |
| WO-1993025566-A1 | DEUTERATED NUCLEOSIDES | CHATTOPADHYAYA JYOTI (SE) | 1993-12-23 | — | — | WO | claimed |
| EP-3818066-B1 | DOUBLE COUPLING METHOD FOR OLIGONUCLEOTIDE SYNTHESIS | AGILENT TECHNOLOGIES INC (US) | 2022-06-15 | — | — | EP | disclosed |
| US-20210347645-A1 | Macroporous Controlled Porosity Silica Gel Suitable For Oligonucleotide Synthesis | CHEMGENES CORPORATION | 2021-11-11 | — | — | US | disclosed |
| EP-3906997-A2 | MACROPOROUS CONTROLLED POROSITY SILICA GEL SUITABLE FOR OLIGONUCLEOTIDE SYNTHESIS | Chemgenes Corporation (US) | 2021-11-10 | — | — | EP | disclosed |
| EP-3818066-A1 | DOUBLE COUPLING METHOD FOR OLIGONUCLEOTIDE SYNTHESIS | Agilent Technologies, Inc. (US) | 2021-05-12 | — | — | EP | disclosed |
| US-10597421-B2 | Protected monomer and method of final deprotection for RNA synthesis | AGILENT TECHNOLOGIES, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| EP-1307469-A1 | NUCLEIC ACID BINDING COMPOUNDS CONTAINING PYRAZOLO[3,4-D]PYRIMIDINE ANALOGUES OF PURIN-2,6-DIAMINE AND THEIR USES | BOEHRINGER MANNHEIM GMBH (DE) | 2003-05-07 | — | — | EP | disclosed |
| WO-2002012263-A1 | NUCLEIC ACID BINDING COMPOUNDS CONTAINING PYRAZOLO[3,4-D]PYRIMIDINE ANALOGUES OF PURIN-2,6-DIAMINE AND THEIR USES | ROCHE DIAGNOSTICS GMBH (DE) | 2002-02-14 | — | — | WO | disclosed |
| US-6140496-A | Precursors for deoxyribonucleotides containing non-standard nucleosides | BENNER, STEVEN | 2000-10-31 | — | — | US | disclosed |
| US-5264448-A | Thioamides, oxazole ring, insecticides, miticides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1993-11-23 | — | — | US | disclosed |
| EP-0394043-A1 | An amide compound and its production and use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1990-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225277-A1 | Process for preparation of cyclic prodrugs of PMEA and PMPA | MPO, PNP, MAOA | DNM1 2698/4885TSHR 3320/4885LMNA 883/4885 |
| US-10597421-B2 | Protected monomer and method of final deprotection for RNA synthesis | NSUN2, RNGTT, RNMT | DNM1 1470/4885TSHR 3650/4885LMNA 260/4885 |
| US-20070203339-A1 | Process for Preparation of Cyclic Prodrugs of PMEA and PMPA | PNP, PHOSPHO1, MPO | DNM1 2736/4885TSHR 3839/4885LMNA 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.